Univariate and multivariate results at the 5-year follow-up
| 1Univariate analysis | Multivariate analysis | |||||
| Group | Total | Outcomes | OR (95% CI) | P value | OR (95% CI) | P value |
| (n=18 072) |
Atypical maculopathy
(n=41; 0.23%) | 0.37 | 0.43 | |||
| No PPS | 15 060 | 32 (0.2%) | Reference | Reference | ||
| PPS | 3012 | 9 (0.3%) | 1.47 (0.67 to 2.95) | 1.35 (0.64 to 2.83)* | ||
| (n=18 072) |
Atypical maculopathy+AMD
(n=543; 3.0%) | 0.14 | 0.13 | |||
| No PPS | 15 060 | 440 (2.9%) | Reference | Reference | ||
| PPS | 3012 | 103 (3.4%) | 1.18 (0.95 to 1.46) | 1.20 (0.95 to 1.51)† | ||
*Variables used in multivariate analysis included age, diabetes, past stroke or transient ischaemic attack, atrial fibrillation/flutter, previous myocardial infarction, arrhythmia and hypertension.
†Variables used in multivariate analysis included age, gender, race, education level, household income, geographical location, index year, diabetes, past stroke or transient ischaemic attack, peripheral vascular disease, malignancy, chronic kidney disease, atrial fibrillation/flutter, congestive heart failure, previous myocardial infarction, arrhythmia and hypertension.
AMD, age-related macular degeneration; PPS, pentosan polysulfate sodium.